Revolutionizing Infection Treatment: Cutting-Edge Approaches in Antimicrobial Stewardship

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Antibiotics Use and Antimicrobial Stewardship".

Deadline for manuscript submissions: 30 October 2025 | Viewed by 965

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Interests: antifungal therapy; antimicrobial stewardship; HIV/AIDS; transplant ID; opportunistic infections; anti-microbial resistance

Special Issue Information

Dear Colleagues,

The global burden of antimicrobial resistance (AMR) is one of the most pressing public health challenges of the 21st century. To prevent further AMR, it is imperative that gaps in knowledge and clinical practice be resolved via cutting-edge clinical strategies, evidence-based tools, and multidisciplinary approaches that optimize antimicrobial therapy.

The aim of this Special Issue is to explore and promote innovative antimicrobial stewardship interventions that enhance the treatment of infections across diverse healthcare settings. This Special Issue seeks to highlight innovative strategies, technologies, and evidence-based practices that improve clinical outcomes, reduce AMR, and ensure the sustainability of effective infection management.

This Special Issue welcomes topics inlcuding innovative diagnostic tools for infection identification and treatment, strategies for personalized antimicrobial therapy, integration of technology and artificial intelligence in antimicrobial stewardship programs, clinical advancements in antimicrobial stewardship in low-resource environments, and advancements in antimicrobial stewardship in outpatient and community-based settings. Contributions are encouraged from diverse disciplines, not limited to microbiology, pharmacology, epidemiology, public health, and clinical medicine to provide a multidisciplinary perspective regarding treatment optimization. Additionally, original research articles and reviews are welcome and encouraged.

We look forward to receiving your contributions.

Dr. Jacob Myles Keck
Dr. Aleksandra Barac
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antimicrobial stewardship
  • antimicrobial resistance
  • infection treatment optimization
  • rapid diagnostics
  • technology in healthcare

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

25 pages, 473 KB  
Review
“Dusting Off the Cobwebs”: Rethinking How We Use New Antibiotics
by Jacob Myles Keck, Jacob Schultz and Alina Viteri
Antibiotics 2025, 14(9), 862; https://doi.org/10.3390/antibiotics14090862 - 27 Aug 2025
Viewed by 639
Abstract
Antimicrobial resistance continues to escalate worldwide, threatening effective medical care, patient safety, and global health security. Traditional antibiotics are increasingly unreliable against multidrug-resistant pathogens, resulting in delayed appropriate therapy, prolonged illness, higher healthcare costs, and increased mortality. In this context, antimicrobial stewardship must [...] Read more.
Antimicrobial resistance continues to escalate worldwide, threatening effective medical care, patient safety, and global health security. Traditional antibiotics are increasingly unreliable against multidrug-resistant pathogens, resulting in delayed appropriate therapy, prolonged illness, higher healthcare costs, and increased mortality. In this context, antimicrobial stewardship must evolve beyond the preservation of older drugs to include the judicious, evidence-based use of newer antibiotics. When used empirically in high-risk scenarios, novel agents can improve clinical outcomes by ensuring timely, effective coverage against MDR organisms while reducing the need for broad-spectrum combinations that drive collateral resistance and adverse effects. A major challenge, however, is the underutilization of these agents, which not only limits patient benefit but also undermines incentives for continued pharmaceutical innovation. To address this gap, stewardship programs must incorporate strategies for appropriate empiric deployment of new antibiotics, guided by local epidemiology, risk stratification, rapid diagnostics, and multidisciplinary decision-making. A coordinated global effort, linking stewardship, innovation, and policy reform, will be critical to optimize the role of novel antimicrobials in clinical practice moving forward. Full article
Back to TopTop